A method of preventing weakness in a patient with Parkinson's disease or of improving or restoring muscle strength of a patient with Parkinson's disease, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to prevent, improve or restore to normal said muscle strength, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 where R] is one of an N-acyl group, a substituted or unsubstiruted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
Karadas, A
In the flip-flop model, parameters including volume of distribution, clearance, and elimination processes of the drug as described for conventional oral dosing remain unchanged, but for OLAI, the concentrationtime profile of the drug is under the control of a very slow absorption process
"This statement has not been evaluated by the Food and Drug Administration
Int J Mol Sci 24(3):2430
